UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 20:41:17 17/05/2024 BST | ||
| 0.57 EUR | +3.64% |
|
| Current month | +128.00% | ||
| 1 month | +32.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.57 | +3.64% |
| 16/05/24 | 0.55 | +12.24% |
| 15/05/24 | 0.49 | +13.95% |
| 14/05/24 | 0.43 | -10.42% |
| 13/05/24 | 0.48 | +11.63% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 08:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1KPJ |
| ISIN | DE000HD1KPJ3 |
| Date issued | 02/01/2024 |
| Strike | 600 $ |
| Maturity | 15/01/2025 (243 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.71 € |
|---|---|
| Lowest since issue | 0.11 € |
| Spread | 0.07 € |
| Spread % | 10.94% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
